Research progress of chimeric antigen receptor T cell immunotherapy in hematologic malignancies

In recent years, genetically modified autologous T cell therapy has made remarkble achievements in clinical trials of oncotherapy, among which chimeric antigen receptor T-cell (CAR-T) immunotherapy has generated dramatic clinical successes in patients with acute lymphoblastic leukemia (ALL). Chimeric antigen receptor (CAR) is a hybrid molecule composed of antigen-binding domains fused to T-cell activation and costimulatory domains. CAR-T can bind tumor cells specifically. Unlike traditional medicines, CAR-T has potential to eradicate widespread cancer and provides long-term protection in the form of immunologic memory. Therefore, CAR-T immunotherapy is attracting more and more attention, and has become a promising therapy in hematologic malignancies, especially B-cell malignancies. This review will discuss the currently clinical trials of CAR-T immunotherapy in hematologic malignancies. Key words: Lymphoma, B-cell; Leukemia; Multiple myeloma; Chimeric antigen receptor T cell immunotherapy